ISRCTN12367117进行中（未招募）1 期
A phase I, open-label, single-period, single-dose study to assess the absorption, metabolism, and excretion of oral [14C]NST-6179 (Orziloben) in healthy male subjects
orthSea Therapeutics B.V.0 个研究点目标入组 8 人开始时间: 2024年7月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •1.Must provide written informed consent.
- •2.Must be willing and able to communicate and participate in the whole study.
- •3.Aged 30 to 65 years inclusive at the time of signing informed consent.
- •4.Must agree to adhere to the contraception requirements defined in the protocol.
- •5.Healthy males according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs, 12-lead ECG, and clinical laboratory tests without any clinically significant abnormalities.
- •6.Body mass index (BMI) of 18.0 to 32.0 kg/m², inclusive, as measured at screening.
- •7.Must have regular bowel movements (i.e. average stool production of =1 and =3 stools per day).
排除标准
- •1.Serious adverse reaction or serious hypersensitivity to any drug or formulation excipients.
- •2.Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active.
- •3.History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic respiratory or GI disease, neurological or psychiatric disorder, as judged by the investigator.
- •4.Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening.
- •5.Clinically significant abnormal clinical chemistry, haematology or urinalysis as judged by the investigator (laboratory parameters are listed in the protocol). Subjects with Gilbert’s Syndrome are not allowed.
- •6.Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) 1 and 2 antibody results.
- •7.Evidence of renal impairment at screening, as indicated by an estimated creatinine clearance (CLcr) of <80 mL/min using the Cockcroft-Gault equation.
- •8.Subjects who have received any IMP in a clinical research study within the 90 days prior to Day 1, or less than 5 elimination half-lives prior to Day 1, whichever is longer.
- •9.Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017, shall participate in the study.
- •10.Subjects who have been administered IMP in an ADME study in the last 12 months.
- •11.Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood.
- •12.Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies, including topical medications, (other than up to 4 g of paracetamol per day in the 14 days prior to Day 1, or less than 5 elimination half-lives prior to Day 1, whichever is longer). Exceptions may apply, as determined by the investigator, if each of the following criteria are met: medication with a short half-life if the washout is such that no pharmacodynamic activity is expected by the time of dosing with IMP; and if the use of medication does not jeopardise the safety of the trial subject; and if the use of medication is not considered to interfere with the objectives of the study. COVID-19 vaccines are accepted concomitant medications.
- •13.Subjects who are using medications or products that are inhibitors or inducers of CYP2C9 or uridine 5'-diphospho-glucuronosyltransferase (UGT) in the 14 days (for CYP2C9/UGT inhibitors)/28 days (for CYP2C9/UGT inducers) prior to Day 1, or less than 5 elimination half-lives prior to Day 1, whichever is longer.
- •14.Use or intention to use any medications or products known to alter drug absorption, metabolism, or elimination processes, including St John’s Wort, in the 30 days prior to Day 1. Exceptions may apply, as determined by the investigator.
- •15.History of any drug or alcohol abuse in the past 2 years.
- •16.Regular alcohol consumption in males >21 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type).
- •17.A confirmed positive alcohol breath test at screening or admission.
- •18.Current smokers and those who have smoked within the last 12 months.
- •19.Current us
研究者
相似试验
已完成
1 期
A study in healthy post-menopausal female volunteers to assess how the test medicine [14C]AZD9833 is taken up, broken down and removed from the bodyER-positive, HER2-negative breast cancerCancerISRCTN46127225AstraZeneca (Sweden)6
进行中（未招募）
1 期
A study to evaluate the effect of itraconazole and carbamazepine on the processing of fenebrutinib by the body in healthy participantsHealthy volunteersISRCTN12005942Genentech32
已完成
1 期
A study to evaluate the effects of multiple doses of itraconazole and carbamazepine on processing of giredestrant by the body in healthy female participantsHealthy female participantsISRCTN16366416Genentech33
进行中（未招募）
1 期
An early stage study looking at how much betrixaban gets into the blood of young people after they take a single capsule, and to see if it is safe to do so.Pediatric patients who are assessed to be at risk for Venous thromboembolism (VTE) but does not require immediate anticoagulant therapy, for example:a. Has previous thrombosis and completed a course of anti-coagulant therapy, and is considered to have a risk for recurrence of VTE, orb. Has any stable disease with a risk for arterial or venous thrombotic disorder, orc. Has any functional CVAD (Central Venous Access Device) in the upper or lower venous system.MedDRA version: 20.0Level: PTClassification code 10053468Term: Anticoagulant therapySystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2018-002562-40-GBPortola Pharma UK Ltd33
已完成
1 期
A study to investigate the effects of food and administration of different forms of mavodelpar on the safety and concentration of mavodelpar in the bloodHealthy VolunteersISRCTN85791974Reneo Pharma Ltd (United Kingdom)32